格隆汇1月12日丨心玮医疗-B(06609.HK)发布公告，2026年1月12日耗资243.32万港元回购4万股，回购 价格每股59.8-62.2港元。 ...

心玮医疗-B(06609)发布公告，于2026年1月12日，该公司斥资243.32万港元回购4万股股份，每股回购价 格为59.8-62.2港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期： 2026年1月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 ...

心玮医疗-B回购明细 | 日期 | 回购股数 （万股） | 回购最高价 （港元） | 回购最低价 （港元） | 回购金额 （万港元） | | --- | --- | --- | --- | --- | | 2026.01.09 | 6.88 | 61.100 | 57.550 | 405.68 | | 2026.01.08 | 0.55 | 59.800 | 58.750 | 32.58 | | 2026.01.07 | 3.82 | 58.750 | 56.600 | 220.01 | | 2026.01.02 | 2.72 | 54.600 | 53.400 | 146.62 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 自1月7日以来公司已连续3日进行回购，合计回购11.25万股，累计回购金额658.26万港元。 其间该股累 计上涨5.25%。 今年以来该股累计进行4次回购，合计回购13.97万股，累计回购金额804.89万港元。（数据宝） （原标题：心玮医疗-B(06609.HK)1月9日回购6.88万股，耗资405.68万港元） 证券时报•数据宝统计，心玮医疗-B在港交所公告显示 ...

相关事件 格隆汇1月9日丨心玮医疗-B(06609.HK)发布公告，2026年1月9日耗资405.68万港元回购6.88万股，回购 价格每股57.55-61.1港元。 心玮医疗-B(06609.HK)1月9日耗资405.68万港元回购6.88万股 脑机接口风口下的价值重估，心玮医疗- B(6609.HK)的技术卡位与资本进阶 ...

心玮医疗-B(06609)发布公告，该公司于2026年1月9日斥资405.68万港元回购6.88万股股份，每股回购价 格为57.55-61.1港元。 ...

智通财经APP讯，心玮医疗-B(06609)发布公告，该公司于2026年1月9日斥资405.68万港元回购6.88万股 股份，每股回购价格为57.55-61.1港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期： 2026年1月9日 FF305 FF305 確認 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份 ...

Summary of New Wei Medical Conference Call Company Overview - New Wei Medical focuses on interventional brain-machine interface technology, utilizing a minimally invasive approach through the jugular vein to access brain vessels for signal collection, differentiating itself from invasive technologies like those developed by Musk's company [2][5] Key Points and Arguments - **Product Development Timeline**: New Wei Medical plans to complete type testing and animal experiments by mid-2026, initiate clinical enrollment in the second half of 2026, and expects to finish all patient enrollment and submit for regulatory approval by 2028 [2][3][4] - **Independent Subsidiary**: The company has established an independent subsidiary named "Wei Brain Technology" to focus on the development of interventional brain-machine interfaces and related investment collaborations, with plans to expand the team to 20 members [2][9] - **Technical Specifications**: The interventional brain-machine interface device uses a nickel-titanium alloy stent with electrode configurations of 4 or 16 channels, with signal processing chips placed subcutaneously beneath the clavicle [2][8] - **Animal Testing Results**: Animal experiments have shown stable signal strength, with a small-tailed sheep experiment maintaining 97%-98% signal strength after 18 months, validating the feasibility of the technology [2][11] Competitive Landscape - **Comparison with Musk's Technology**: New Wei Medical's approach avoids the need for craniotomy, which is required by Musk's invasive technology. This results in lower surgical risks and higher patient acceptance. The company claims its method ensures stable signal transmission due to the encapsulation of the electrode stent by the vessel wall, preventing displacement issues [5][10] Clinical Trial Plans - **First Patient Enrollment**: The company plans to conduct its first clinical trial in 2026, targeting 30-50 patients primarily for limb rehabilitation indications, with a follow-up period of approximately six months [4][10] - **Regulatory Recognition**: New Wei Medical is the only approved project for interventional technology routes in a national initiative co-hosted by the Ministry of Industry and Information Technology and the National Medical Products Administration, indicating recognition of its innovative technology [4][6] Challenges and Future Directions - **Technical Limitations**: The interventional approach may face challenges in accessing smaller, more distal blood vessels, necessitating the design of smaller electrode stents for broader brain area applications [11][12] - **Future Applications**: The company aims to extend its technology from motor function areas to visual and auditory functions, as well as explore emotional management and other research directions [11][12] Additional Insights - **Market Potential**: With 2,500 hospitals in China capable of performing the minimally invasive procedure, New Wei Medical is positioned to leverage a broad market for its technology [5] - **Investment and Collaboration**: The subsidiary aims to attract external partnerships and capital to enhance its operational capabilities and cover more consumer-level application scenarios [9]

Core Insights - Elon Musk's Neuralink plans to start large-scale production of brain-machine interface devices in 2026, indicating a shift from clinical trials to commercialization in the industry [1] - The domestic brain-machine interface sector is experiencing favorable policies and market conditions, including the establishment of medical service pricing and discussions on insurance coverage for invasive procedures [1] - Xinwei Medical's subsidiary, Weina Zhiliang, has officially settled in Shanghai's brain-machine interface industrial cluster, focusing on R&D and clinical application of brain-machine interface technology [1] Industry Trends - The global competition in the brain-machine interface sector is fundamentally a contest of technological routes and clinical implementation capabilities [3] - Neuralink's invasive approach has precision advantages but is limited by surgical risks, while Xinwei Medical's interventional route mitigates these risks and aligns with its expertise in neuro-intervention [3] - Xinwei Medical's project for an interventional brain-machine interface system targeting motor function disorders has been selected for national AI medical device innovation support, positioning the company as a leader in the field [3] Market Potential - The global brain-machine interface market is projected to reach $12.4 billion by 2034, with a compound annual growth rate of 17% from 2025 to 2034 [7] - Xinwei Medical's technology addresses critical issues of accessibility and payment feasibility in high-value medical technology, aligning with the growing demand from patients with conditions like Parkinson's and post-stroke motor disorders [7] - The company's recent establishment in Shanghai's industrial cluster enhances its ability to connect with cutting-edge resources in talent, technology, and clinical applications [7] Financial Performance - Xinwei Medical's revenue for the first half of 2025 reached 186 million yuan, a year-on-year increase of 44.39%, marking a return to profitability [13] - The company's gross margin improved to 68.2%, driven by a robust business structure in ischemic and hemorrhagic stroke interventions [13] - The management's capital actions, including share buybacks and executive stock purchases, reflect confidence in the company's long-term value [10][11] Strategic Initiatives - Xinwei Medical has initiated an A-share IPO process, aiming to leverage its financial data from 2025 to enhance its capital platform and support ongoing business expansion [15] - The IPO is expected to improve market liquidity, reduce financing costs, and enhance brand credibility, facilitating the entry of its interventional devices into hospitals [17] - The company is positioned to capitalize on the growing neuro-regulation market, leveraging its technological advantages in brain-machine interfaces [17] Conclusion - Xinwei Medical's stock price has rebounded significantly, reflecting the convergence of its technological strategy, capital actions, and financial performance [18] - The company is well-positioned to seize opportunities in the brain-machine interface market, supported by its strategic initiatives and solid performance metrics [21] - Long-term value reassessment for Xinwei Medical is just beginning, as it stands at the intersection of industry growth and its own development trajectory [22]